Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Chugai Pharmaceutical
Biotech
Chugai drops only AI-assisted antibody from pipeline
With the scrapping of phase 1 chronic disease candidate BRY10, Chugai now has no antibodies designed using its AI platform in clinical trials.
Darren Incorvaia
Jan 30, 2026 10:55am
JPM26: Chugai chases new science and name recognition
Jan 16, 2026 5:28am
Hansoh, Chugai ink separate and lucrative licensing agreements
Oct 17, 2025 11:04am
Chugai inks $250M deal for Gero’s age-related disease targets
Jul 7, 2025 3:00am
